Thorough and intensive QTc Studies

Richmond Pharmacology has globally recognised expertise in cardiac safety, intensive ECG studies, cardiology overreading, statistical analysis, reporting and publishing.

We are proud of our successful track record which is demonstrated in our published studies.

We provide sponsors with FDA compliant analysis methods, and the option to include a non-pharmacological method of proving assay sensitivity. Our unique and innovative approach means that we conduct our studies and prove assay sensitivity as a standard feature. This has provided quality data in many Japanese bridging, SAD and MAD studies, eliminating the need for a dedicated TQT study.

x

Examples of our credentials in TQT and QTc Studies

Food effect on QT interval. Our research has confirmed food impacts cardiac repolarisation by shortening the J-T peak. This can be used in our studies as a non-pharmacological method of proving assay sensitivity. Learn more here.

Sex hormones and the QT Interval. Research funded by Richmond Pharmacology identified a significant influence of estradiol on QTcF suggesting a menstrual cycle could influence the QTc. Learn more here.

Short start-up times of 4-6 weeks, rapid data readout

Our study data is well respected by regulators such as FDA, EMA and PMDA. Our statistical team specialise in statistical analysis concentration effect modelling, reporting, and publishing.

Get in touch today

Why choose Richmond Pharmacology for TQT & QTc Studies

TAP OR CLICK A BLOCK BELOW TO LEARN MORE

Low data variability

Our core ECG laboratory provides a centralised system for all our studies.

Read more +

Exceptional ECG generation

We undertake and analyse several cardiological assessments using state-of-the-art equipment.

Read more +

Experts in cardiac safety

Richmond Pharmacology’s Core ECG Laboratory team are based within St George’s Hospital Medical School, London.

Read more +

Our in-house cardiac experts include Professor John Camm and Dr Jorg Taubel. Together, they ensure your QTc study is best-in-class. Meet the team.

Latest news

Director of Operations, Keith Berelowitz, has been appointed as the Research Ethics Committee Chair for the Health Research Authority.

January 19, 2023
Keith Berelowitz will be responsible for ensuring that all ethical possibilities are explored in relation to new research.
Read more

Unlocking the potential of data sharing

January 4, 2023
Dilshat Djumonov explores how GDPR is central to protecting private information while presenting unique challenges to the pharmaceutical clinical trials industry.
Read more

Events

13th International Workshop on Regulatory Requirements and Current Scientific Aspects on the Preclinical and Clinical Investigation of Drug-Drug Interactions

Sunday, June 4th to Tuesday June 6th 2023
Exchange research-based knowledge on drug-drug interactions (DDIs) among all interested stakeholders from pharmaceutical industry, regulatory authorities, academic and health care delivery backgrounds and perspectives.
View event